YH004 / Biocytogen - LARVOL DELTA

BIO-Europe Spring 2024 | BIOcyto invites you for a 1-on-1 appointment [Google translation] (Biocytogen Press Release) - "Biocytogen's Antibody Drug Business (BDL) team will participate in the BIO-Europe Spring conference to be held in Barcelona, ​​Spain, from March 18 to 20, 2024, and participate in 1-on-1 appointments and exchanges...Antibodies and antibody-like molecules available for cooperation include: 40+ PCC stage antibody molecules: B7-H3, Siglec-15, TNFR2, MUC16, NKG2D, ROR1, TIGIT, IL-2RA, AMHR2, CD73, CD40 (antagonist) antibodies, etc...60+ fully human GPCR single/double antibody projects: CCR8, GPRC5D, LGR5, CCR2, etc...The five clinical-stage antibody molecules available for collaboration are: YH008...YH003 (CD40 agonist monoclonal antibody)...YH001 (CTLA-4 monoclonal antibody)...YH002...YH004 (4-1BB monoclonal antibody)....The antibody molecules in Biocytogen's antibody library can be directly provided to global pharmaceutical companies and biotechnology companies for evaluation and licensing cooperation."

Licensing / partnership • Hematological Malignancies • Melanoma • Mucosal Melanoma • Oncology • Sarcoma • Skin Cancer • Soft Tissue Sarcoma • Solid Tumor

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: Eucure (Beijing) Biopharma Co., Ltd | Recruiting ➔ Completed | N=80 ➔ 8 | Trial completion date: Jun 2024 ➔ Jul 2023 | Trial primary completion date: Jan 2024 ➔ Jul 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: Eucure (Beijing) Biopharma Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=38 | Not yet recruiting | Sponsor: Eucure (Beijing) Biopharma Co., Ltd

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: Eucure (Beijing) Biopharma Co., Ltd; Not yet recruiting ➔ Recruiting; Initiation date: Sep 2021 ➔ Dec 2021

Clinical • Enrollment open • Trial initiation date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase I Clinical Trial of YH004 (Anti-4-1BB Monoclonal Antibody) in Australia (PRNewswire) - "Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of YH004 (anti-4-1BB monoclonal antibody, mAb) (No. YH004002) in Australia. The study is an open-label, multi-center, classical dose-escalation phase I study of YH004 monotherapy or YH004 in combination with anti-PD-1 mAb. Subjects are patients with advanced solid tumors or relapsed/refractory non-Hodgkin's lymphoma (R/R NHL)."

Trial status • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor